ES2643083T3 - Profármacos de cianoguanidina - Google Patents

Profármacos de cianoguanidina Download PDF

Info

Publication number
ES2643083T3
ES2643083T3 ES15150976.7T ES15150976T ES2643083T3 ES 2643083 T3 ES2643083 T3 ES 2643083T3 ES 15150976 T ES15150976 T ES 15150976T ES 2643083 T3 ES2643083 T3 ES 2643083T3
Authority
ES
Spain
Prior art keywords
ethoxy
methoxyethoxy
cyano
compound
hexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES15150976.7T
Other languages
English (en)
Spanish (es)
Inventor
Ernst Torndal Binderup
Pernill-Julia Vig Hjarnaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Application granted granted Critical
Publication of ES2643083T3 publication Critical patent/ES2643083T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15150976.7T 2000-11-21 2001-11-14 Profármacos de cianoguanidina Expired - Lifetime ES2643083T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25207800P 2000-11-21 2000-11-21
US252078P 2000-11-21

Publications (1)

Publication Number Publication Date
ES2643083T3 true ES2643083T3 (es) 2017-11-21

Family

ID=22954502

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15150976.7T Expired - Lifetime ES2643083T3 (es) 2000-11-21 2001-11-14 Profármacos de cianoguanidina
ES01983436.5T Expired - Lifetime ES2549260T3 (es) 2000-11-21 2001-11-14 Profármacos de cianoguanidina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01983436.5T Expired - Lifetime ES2549260T3 (es) 2000-11-21 2001-11-14 Profármacos de cianoguanidina

Country Status (16)

Country Link
US (1) US6525077B2 (https=)
EP (2) EP1339686B1 (https=)
JP (1) JP4521157B2 (https=)
KR (1) KR100871577B1 (https=)
CN (1) CN100368401C (https=)
AU (3) AU1494702A (https=)
BR (1) BR0115514A (https=)
CA (1) CA2426601C (https=)
CZ (1) CZ305764B6 (https=)
ES (2) ES2643083T3 (https=)
HU (1) HU230544B1 (https=)
IL (2) IL155483A0 (https=)
MX (1) MXPA03004394A (https=)
PL (1) PL224371B1 (https=)
RU (1) RU2312858C2 (https=)
WO (2) WO2002042265A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
CA2485351C (en) * 2002-05-17 2011-12-06 Leo Pharma A/S Cyanoguanidine prodrugs
BR0309988A (pt) * 2002-05-17 2005-02-22 Leo Pharma As Composto, composição farmacêutica, métodos para tratar ou melhorar doenças ou condições proliferativas e doenças inflamatórias, e, uso de um composto
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
AU2004228668B2 (en) * 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
ES2572777T3 (es) 2004-12-22 2016-06-02 Leo Pharma A/S Compuestos novedosos de cianoguanidina
EP1917244A2 (de) 2005-08-24 2008-05-07 Abbott GmbH & Co. KG Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
WO2009072004A2 (en) * 2007-09-26 2009-06-11 Gemin X Pharmaceuticals Canada, Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
US8173677B2 (en) * 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
US8101606B2 (en) 2007-11-12 2012-01-24 Washington University Neurofibromin pathway modulators
RU2011111728A (ru) 2008-08-29 2012-10-10 Топотаргет А/С (Dk) Новые производные мочевины и тиомочевины
CA2751495C (en) 2009-02-06 2013-08-20 Tianjin Hemay Bio-Tech Co., Ltd. Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
US9224007B2 (en) * 2009-09-15 2015-12-29 International Business Machines Corporation Search engine with privacy protection
US9600134B2 (en) 2009-12-29 2017-03-21 International Business Machines Corporation Selecting portions of computer-accessible documents for post-selection processing
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
WO2012137225A1 (en) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
US9195853B2 (en) 2012-01-15 2015-11-24 International Business Machines Corporation Automated document redaction
CN106905297A (zh) * 2012-06-15 2017-06-30 加利福尼亚大学董事会 用于脑癌的新颖治疗剂
JP2015522028A (ja) * 2012-06-27 2015-08-03 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッドAlzheimer’S Institute Of America, Inc. 化合物とその治療用途
AU2013326850B2 (en) * 2012-10-04 2017-09-21 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
US9892278B2 (en) 2012-11-14 2018-02-13 International Business Machines Corporation Focused personal identifying information redaction
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
MX394452B (es) 2015-02-27 2025-03-21 Curtana Pharmaceuticals Inc Inhibicion de la actividad de olig2.
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
US20200138964A1 (en) * 2017-04-25 2020-05-07 Seikagaku Corporation Tertiary amine compound or imine compound-polymer conjugate and production method therefor
EP3590927A1 (en) * 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
US11174229B2 (en) 2018-10-29 2021-11-16 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5938390A (en) * 1989-06-26 1991-01-17 Research Foundation Of The State University Of New York, The Bis-acyloxymethyl derivatives
GB9219472D0 (en) 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
GB9711124D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711119D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711123D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
WO2000061561A1 (en) * 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Cyanoguanidine compounds
WO2000061559A1 (en) * 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. N-substituted cyanoguanidine compounds

Also Published As

Publication number Publication date
US6525077B2 (en) 2003-02-25
PL224371B1 (pl) 2016-12-30
WO2002042265A2 (en) 2002-05-30
HU230544B1 (hu) 2016-11-28
AU2002223511A1 (en) 2002-06-03
EP2894149A1 (en) 2015-07-15
CN100368401C (zh) 2008-02-13
CN1589262A (zh) 2005-03-02
AU2002214947B2 (en) 2007-02-15
EP1339686A2 (en) 2003-09-03
IL155483A (en) 2010-12-30
JP2004520282A (ja) 2004-07-08
CA2426601A1 (en) 2002-05-30
RU2312858C2 (ru) 2007-12-20
HUP0400564A2 (hu) 2004-06-28
EP1339686B1 (en) 2015-09-16
MXPA03004394A (es) 2004-04-20
EP2894149B1 (en) 2017-08-02
CZ20031303A3 (en) 2004-04-14
BR0115514A (pt) 2003-12-30
CA2426601C (en) 2015-01-13
JP4521157B2 (ja) 2010-08-11
AU1494702A (en) 2002-06-03
WO2002042265A3 (en) 2002-08-15
KR20030051861A (ko) 2003-06-25
IL155483A0 (en) 2003-11-23
HK1212678A1 (en) 2016-06-17
WO2002042276A1 (en) 2002-05-30
HUP0400564A3 (en) 2008-03-28
CZ305764B6 (cs) 2016-03-09
HK1073297A1 (zh) 2005-09-30
KR100871577B1 (ko) 2008-12-02
ES2549260T3 (es) 2015-10-26
PL362864A1 (en) 2004-11-02
US20020165201A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
ES2643083T3 (es) Profármacos de cianoguanidina
US5066823A (en) Preparation of 5-acylamino-2,4,6-triiodo- or tribromo-benzoic acid derivatives
AU2011295171B2 (en) New process for the preparation of intermediates useful for the manufacture NEP inhibitors
ES2236032T3 (es) Sales estables de nuevos derivados de 3,3-difenil-propil-aminas.
ES2549087T3 (es) Derivados de aminodihidrotiazina como inhibidores de BACE para el tratamiento de la enfermedad de Alzheimer
PT1430020E (pt) Sais de amónio quaternário de omega-aminoalquilamidas de ácidos r-2-arilpropiónicos e composições farmacêuticas que os contêm
WO1999001419A1 (en) Processes for producing 2-aminomalonic acid derivatives and 2-amino-1,3-propanediol derivatives, and intermediates for producing the derivatives
SI9200186A (en) Process for the preparation of fluoxetin and new intermediates
US4597903A (en) Process for the direct preparation of N,N-disubstituted derivatives for 4,13-diaza-18-crown-6
DD298911A5 (de) Azetidine, ihre herstellung und verwendung als zwischenprodukte fuer die herstellung von biologisch wirksamen substanzen
US10836717B2 (en) Reagents for fluorosulfating alcohols or amines
RU2157363C2 (ru) Производные валинамида, способ их получения и способы получения промежуточных продуктов
PT727423E (pt) Processo para a preparacao de derivados de sulfonilureia e de intermediarios para este processo
CA2552087C (en) Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
NO146862B (no) Jodbenzenderivater for anvendelse som roentgenkontrastmidler
US5723647A (en) N-(4-bromo-2-fluorobenzyl)carbamates and a process for their preparation
US2670360A (en) Quaternary ammonium salts of basic derivatives of substituted cinnamic acids and methods of producing same
JP2002241382A (ja) モノアザチアクラウン化又はモノアザオリゴチオエチレングリコール化スピロベンゾピラン
KR20030031968A (ko) 광학적으로 활성인 형태의 아지리딘-2-카르복실산 유도체 및 그의 제조 방법
JP3174566B2 (ja) アミノアルカン誘導体
Hoefler et al. Syntheses of a Series of Electron Donor and Electron Acceptor Derivatives
KR960010348B1 (ko) 새로운 2,4-디히드로-3h-1,2,4-트리아졸-3-온 유도체 및 그 제조방법
SE460605B (sv) Foerfarande foer framstaellning av 4-amino-1,2-hydrokarbyl-pyrazolidiner
ES2253388T3 (es) Procedimiento para preparar esteres del acido aril-iminometil-carbamico.
Casper et al. Synthesis of N4‐substituted [1, 3, 4] oxadiazinan‐2‐ones derived from norephedrine